Macrometastasis at selective lymph node biopsy: A practical going-for-the-one clinical scoring system to personalize decision making

Table 2 Univariate analysis of 95 patients with presence of sentinel lymph nodes with macrometastases

	No additional metastatic lymph nodes	Additional metastatic lymph nodes	P value
Age
< 40	66%	44%	0.04
≥ 40	32.6%	67.4%
Hormonal status
Premenopausal	70%	30%	NS
Postmenopausal	60%	40%
T stage
T1	75.8%	24.2%	< 0.05
T2	47%	53%
T3	0	100%
Tumor size
≤ 15 mm	85%	15%	< 0.05
> 15 mm	49%	51%
Histologic type
Ductal carcinoma	67.1%	32.9%	NS
Lobular carcinoma	47%	53%
Grade
I + II	68.6%	31.4%	NS
III	54%	46%
Molecular subtype
Luminal A/B	65.6%	34.4%	< 0.05
Basal	22.2%	77.8%
HER2	100%	0
LVI
Present	66.7%	33.3%	NS
Absent	61.5%	38.5%
Number of positive SLN
1	69.6%	31.4%	< 0.05
≥ 2	43.7%	66.3%
ACOSOG Z0011 criteria
≤ 2 SLN+	68.5%	31.5%	< 0.05
> 2 SLN+	16%	84%

LVI: Lymphovascular invasion; NS: Not significant; SLN: Sentinel lymph nodes.